In our previous study, an azobenzene-based combi-nitrosourea prodrug, named AzoBGNU, was synthesized to selectively sensitize the oxygen-deficient tumor cells to the chloroethylating agent by achieving hypoxia-targeting inhibition of AGT. Here, AGT is linked to neoplasm.